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 Introduction 
 Psoriasis is a chronic inflammatory disease of the skin 
and can be treated both with topical and systemic drugs, 
depending on severity  [1] . The introduction of biologics 
for moderate-to-severe psoriasis resulted in both in-
creased treatment success and fewer side effects  [2] . Upon 
introduction of biologics, topicals are usually not actively 
stopped by treating dermatologists  [3] . Instead, patients 
are free to add moisturizers or topical drugs depending 
on remaining disease activity such as remaining plaques 
on the shins.
 It is not clear whether adding active topical agents to 
adalimumab yields an advantage for the patients. Instead, 
the BELIEVE study showed that monotherapy with ada-
limumab was more efficacious at week 16 than adalimu-
mab combined with topical corticosteroids and vitamin 
D analogues  [4] . The PASI75 responses between patients 
with and without prior anti-TNFs were similar for topical 
treatments regardless of whether the participants used 
calcipotriol +/– corticosteroids or placebo  [3, 5] .
 Moisturizers with urea and salicylic acid have been 
shown to increase glucocorticoid penetration (steroid-
sparing effects). Moisturizer 1 ! per day and betametha-
sone 1 ! per day is equally effective as betamethasone 2 ! 
per day  [6] . It could be shown that an ointment with 10% 
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 Abstract 
 Background: Biologics are used increasingly to treat mod-
erate-to-severe psoriasis. Here the topical treatment habits 
(corticosteroids and vitamin D derivates) and moisturizer 
use of 97 Swiss patients (male 65, female 32) receiving ada-
limumab have been evaluated.  Methods: Using a short 
cross-sectional survey the pharmacist asked patients during 
telephone contact about their topical treatment habits and 
 psoriasis activity.  Results: 47 patients with adalimumab 
monotherapy were still free of psoriatic lesions after a lon-
ger follow-up of 13 months of therapy; 8 of them still used 
topical treatment. In contrast, 38 of 50 patients with remain-
ing lesions used topicals. More than 75% of patients indi-
cated that the perceived efficacy of additional topical ther-
apy was  6 5 on a visual analog scale (0–10). The use of mois-
turizers did not correlate with disease activity.  Conclusion: 
Topical treatment use by adalimumab patients is associated 
with remaining disease activity. 83% of patients without re-
sidual plaques (40% of all adalimumab patients) are able to 
stop topical treatment completely. 
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urea for 2 weeks increased stratum corneum hydration, 
decreased transepidermal water loss, reduced epidermal 
thickness (–40%) and decreased epidermal proliferation 
(–51%)  [7] . In addition, petroleum jelly (soft paraffin) 
alone can inhibit the Köbner response in psoriasis  [8] .
 If an additional efficacy was achieved by adding topi-
cals to adalimumab  [9] , this might be reflected by pa-
tients’ topical treatment habits. Here the topical treat-
ment habits of a Swiss patient collective serviced by a 
pharmacy specialized in delivering adalimumab to pa-
tients’ homes were studied.
 Methods 
 97 patients (male 65, female 32) with a median age of 50 years 
(SD 13.9 years) and moderate-to-severe psoriasis vulgaris previ-
ously unresponsive to other topical (corticosteroids, vitamin D 
derivates) and/or systemic therapies (PUVA, methotrexate, acitre-
tin, cyclosporin, TNF-  antagonists) were analyzed. During a 
routine telephone contact with patients having opted for home 
delivery of adalimumab, they were asked by the pharmacist about 
their topical treatment habits and psoriasis activity in the form of 
a short cross-sectional survey. Informed consent was given by all 
participants. The interview included questions about previous 
therapies, date of first diagnosis, date of starting adalimumab, 
need of topical care and application (daily, every second day, as 
needed), skin care, remaining/new psoriatic lesions with localiza-
tion, and improvement after starting adalimumab by a verbal rat-
ing scale. ‘As needed’ was defined as a maximum of once weekly.
 Results 
 The median duration of adalimumab therapy at the 
time point of consultation was 13 months (SD 6.9 months). 
The median year of first diagnosis of psoriasis was 1993 
(SD 11.8 years). All patients were interviewed once only, 
between October 2010 and January 2011.
 Previous systemic therapies included UVB/PUVA 
(83.5%), methotrexate (57.7%), acitretin (43.3%), cyclo-
sporin (14.4%), other anti-TNF-  therapies (2.1%) and 
various others (12.4%). 15.5% of patients had three and 
9.3% four previous systemic therapies. Psoriatic arthritis 
was present in 5 of 97 patients.
 47 (48.5%) patients were free of psoriatic lesions after 
starting adalimumab after a mean duration of 13 months 
(SD 6.9 months). 8 of these still used topical therapy, but 
only once per week or less (5 patients corticosteroids and 
3 a combination of corticosteroids and calcipotriol). 
Hence 39 patients (40.2%) unresponsive to other previous 
therapies were free of skin manifestations when receiving 
a monotherapy with adalimumab without using topicals 
( table 1 ).
 50 (51.5%) patients still had psoriatic lesions. Of these, 
38 patients used topicals (20 patients a combination of 
corticosteroids and calcipotriol, 15 corticosteroids and 3 
calcipotriol), but 22 only once per week or less. 12 patients 
with active lesions had stopped topical therapy altogeth-
er. When analyzing all 46 patients who used topicals, just 
16 of them (16% of 97 patients) required the treatment 
more than once weekly. 32 of these patients (33%) evalu-
ated the efficacy of topical treatment on a visual analog 
scale from 0 to 10 and indicated a value of  6 5. When all 
patients who used topicals at any frequency were ana-
lyzed, the perceived efficacy was lower in patients who 
still had lesions ( fig. 1 ). However, we did not find differ-
ences in perceived efficacy between the groups that used 
topicals daily, every second day or on demand. There was 
no correlation of duration of adalimumab vs. the use of 
topical therapy.
 58% of patients with active lesions used moisturizers 
(18 patients daily, 11 patients once per week or less). 40% 
of patients without active lesions used moisturizers (13 
daily, 6 once per week or less) ( table 2 ).
 24 of the remaining 50 patients with psoriatic lesions 
indicated a strong or very strong improvement of skin le-
sions compared to prior to adalimumab. 4 patients (4.1%) 
developed new lesions during therapy with adalimumab.
Table 1. U se of topicals
Active lesions No lesions Total
Topical treatment 38 8 46
No topical treatment 12 39 51
Total 50 47 97
S ignificant at p < 0.0001 (Fisher’s exact test).
Table 2. U se of moisturizers
Active lesions No lesions Total
Moisturizers 29 19 48
No moisturizers 21 28 4 9
To tal 50 47 97
Not significant at p = 0.153 (Fisher’s exact test).
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 Discussion 
 Topical treatment habits of patients treated with ada-
limumab for about 1 year correlated positively with the 
presence of remaining disease (p  ! 0.0001), but use of 
moisturizers did not. The weaknesses of this study are the 
lack of PASI values due to the design as a telephone sur-
vey, missing long-term observation and topical treatment 
consumption control. More than three quarters of pa-
tients indicated that the perceived efficacy of additional 
topical therapy was  6 5 on a visual analog scale (0–10). 
This suggests that subjectively, additional topical treat-
ment is regarded as useful by most patients. Further pro-
spective studies should investigate this question if an ac-
tive guidance of topical therapy with all its long-term ef-
fects is strived for.
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 Fig. 1. Perceived efficacy of topicals by patients who still had le-
sions vs. patients without active psoriatic lesions (Mann-Whitney 
test,  * p  ! 0.05). 
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